ReviewMedicine2026
Autosomal dominant inheritance of a heterozygous mutation in HTRA1: A case report and literature review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleHeterozygous mutations in the gene encoding HtrA serine protease 1 (HTRA1) can cause autosomal dominant cerebral small-vessel disease (CSVD), presenting with clinical features that differ slightly from other hereditary CSVD subtypes. Only a limited number of cases have been documented globally. PATIENT CONCERNS: A 51-year-old man presented with more than 2 years of left lower limb weakness, which had acutely worsened over the preceding day. Brain magnetic resonance imaging (MRI) revealed ischemic demyelinating changes in the white matter. DIAGNOSES: Genetic sequencing identified a heterozygous HTRA1 mutation. Follow-up testing confirmed that both of his daughters also carried the same heterozygous mutation.
interventionsManagement focused on secondary prevention, risk-factor control, and lifestyle modification. OUTCOMES: A 6-month follow-up cranial MRI showed no new lesions, and the patient remained clinically stable without disease progression during 1 year of monitoring. LESSONS: Heterozygous HTRA1 mutations may present as autosomal-dominant CSVD, and genetic testing is central to establishing the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.